13 locations in California and Florida, USA - 11 Oct `23A Study to Compare the Efficacy and Safety of SCENESSE and NB-UVB Light in Patients With Vitiligo

Official title: A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo

The Phase 3 CUV105 trial, sponsored by Clinuvel, Inc., evaluates the safety and efficacy of combining SCENESSE (afamelanotide) with NB-UVB phototherapy for generalized vitiligo, focusing on Fitzpatrick skin types IV–VI to address underrepresented populations. The study aims to determine if this combination therapy achieves superior repigmentation outcomes compared to NB-UVB therapy alone.

Key Details:

  • Study Type: Interventional (Clinical Trial)
  • Phase: Phase 3
  • Estimated Enrollment: Not specified
  • Age Range: 12 years and older
  • Duration: Approximately 308 days, including treatment and follow-up periods


Eligibility Criteria:

Inclusion:

  • Individuals aged 12 years or older
  • Confirmed diagnosis of generalized vitiligo with a Vitiligo Area Scoring Index (VASI) of ≥0.3 on the body and face

Exclusion:

  • Pregnant or lactating females
  • Females of childbearing potential not using adequate contraceptive measures
  • History of melanoma or lentigo maligna
  • Presence of skin cancer lesions
  • Severe liver disease or impairment
  • Allergy to afamelanotide or its implant material

Additional Information: Participants will be randomly assigned to receive either NB-UVB light therapy alone or in combination with SCENESSE implants. The study will assess the percentage of patients achieving significant repigmentation, as measured by the VASI scoring system, over the course of the trial. For more details or to inquire about participation, please visit the official trial page.

Start date: 2023-10-11

Completion date: 2025-06-01

Contact: Head of Clinical Operations

Tel.: +441372860765

Email: clinicaltrials@clinuvel.com

Link: https://clinicaltrials.gov/study/NCT06109649

Clinical Trials Alerts

Sign up and be the first to know when new trials are starting nearby.



Back

FAQOther Questions

  • Who is prone to vitiligo?

    Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...

  • Any link between vitiligo and military service?

    While there isn't specific research directly linking military service to the onset of vitiligo, it's critical to comprehend that vitiligo is a multifaceted disorder influenced b...

  • How long does it take to treat vitiligo?

    Vitiligo, a condition characterized by the loss of skin pigment, can be unpredictable in both progression and treatment. The time it takes to treat vitiligo varies significantly...